Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types

AIDS Research and Human Retroviruses

Volumn 19, Issue 3, 2003, Pages 177-186

  Ketas, Thomas J ^a   Moore, John P ^a   Klasse, Per Johan ^b   Spenlehauer, Catherine ^a,c   Nesin, Mirjana ^a   Frank, Ines ^d   Pope, Melissa ^d   Strizki, Julie M ^e   Reyes, Gregory R ^e   Baroudy, Bahige M ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d POPULATION COUNCIL   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ENFUVIRTIDE; RANTES; UNCLASSIFIED DRUG;

ARTICLE; CELL FUSION; CELL TYPE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MONONUCLEAR CELL; PRIORITY JOURNAL; SEXUAL TRANSMISSION; UMBILICAL CORD BLOOD; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CELL COMPARTMENTATION; CYCLIC N-OXIDES; DENDRITIC CELLS; DRUG INTERACTIONS; FETAL BLOOD; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; PEPTIDE FRAGMENTS; PIPERIDINES; PYRIDINES; RANTES; RECEPTORS, CCR5; VIRUS REPLICATION;

EID: 0345700287     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203763315678     Document Type: Article

References (50)

1. Richman DD: HIV chemotherapy. Nature 2001;410:995-1001.
2. Moore JP and Stevenson M: New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000;1:40-49.
3. Doms RW: Beyond receptor expression: The influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 2000;276:229-237.
4. Donzella GA, Schols D, Lin SW, et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77.
5. + T cells. Science 1995;270:1811-1815.
6. Baba M, Nishimura O, Kanzaki N, et al.: A small molecule non-peptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-5703.
7. Strizki JM, Xu S, Vantuno NE, et al.: SCH-C [SCH 351125], an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-12723.
8. Trkola A, Kuhmann SE, Strizki JM, et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
9. Reynes J, Rouzier R, Kanouni T, et al.: SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects [Abstract 1]. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002.
10. + T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera [SHIV]: Implications for HIV-1 infections of humans. Proc Natl Acad Sci USA 2001;98:658-663.
11. + T cells. J Exp Med 2001;194:1407-1419.
12. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002;76:707-716.
13. Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R, and Yarchoan R: Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis 1998;178:413-422.
14. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, and Steinman RM: Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 1998;72:2733-2737.
15. Pope M, Betjes MG, Romani N, et al.: Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 1994;78:389-398.
16. + T cells. J Exp Med 1995;182:2045-2056.
17. Frankel SS, Wenig BM, Burke AP, et al.: Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science 1996;272:115-117.
18. Hu J, Gardner MB, and Miller CJ: Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa alter intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74:6087-6095.
19. + T cells. Science 1999;286:1353-1357.
20. Stahl-Hennig C, Steinman RM, Tenner-Racz K, et al.: Rapid infection of oral mucosal-associated Lymphoid tissue with simian immunodeficiency virus. Science 1999;285:1261-1265.
21. + T-cell response. J Virol 2002;76:688-696.
22. Jameson B, Baribaud F, Pohlmann S, Ghavimi D, Mortari F, Doms RW, and Iwasaki A: Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol 2002;76:1866-1875.
23. Haase AT: The pathogenesis of sexual mucosal transmission and early stages of infection: Obstacles and a narrow window of opportunity for prevention. AIDS 2001;15(Suppl 1):S10-S15.
24. Ignatius R, Steinman RM, Granelli-Piperno A, et al.: Dendritic cells during infection with HIV-1 and SIV. In: Dendritic Cells, 2nd Ed. (Lotze MT, Thomson AW, eds.). Academic Press, San Diego, California, 2001, pp. 487-504.
25. Frank I and Pope M: The enigma of dendritic cell-immunodeficiency virus interplay. Curr Mol Med 2002;2:229-248.
26. + T cells and monocytes from cord and adult blood. AIDS Res Human Retroviruses 1998;14:607-617.
27. Trkola A, Pomales AP, Yuan H, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
28. Trkola A, Paxton WA, Monard SP, et al.: Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol 1998;72:396-404.
29. Connor R, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
30. Dragic T, Trkola A, Thompson DA, et al.: A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-5644.
31. Kilby JM, Hopkins S, Venetta TM, et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-1307.
32. Trkola A, Matthews J, Gordon C, Ketas T, and Moore JP: A cell-line based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or CXCR4 coreceptor. J Virol 1999;73:8966-8974.
33. Frank I, Piatak M Jr, Stoessel H, Romani N, Bonnyay D, Lifson JD, and Pope M: Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DC): Differential intracellular fate of virions in mature and immature DC. J Virol 2002;76:2936-2951.
34. Schmidtmayerova H, Sherry B, and Bukrinsky M: Chemokines and HIV replication. Nature 1996;382:767.
35. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381;667-673.
36. Trkola A, Gordon C, Matthews J, et al.: The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosoaminoglycans, and also activates a signal transduction pathway that enhances viral infectivity. J Virol 1999;73:6370-6379.
37. Derdeyn CA, Decker JM, Sfakianos JN, et al.: Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is modulated by gp120 interactions with the coreceptor. J Virol 2001;75:8605-8614.
38. Ketas TJ, Frank I, Klasse PJ, et al.: Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol 2003;77:2762-2767.
39. Moore JP: Co-receptors: Implications for HIV pathogenesis and therapy. Science 1997;276:51-52.
40. Wu L, Paxton WA, Kassam N, et al.: CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro J Exp Med 1997;185:1681-1691.
41. O'Brien SJ and Moore JP: The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000;177:99-111.
42. Gonzalez E, Dhanda R, Bamshad M, et al.: Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001;98:5199-5204.
43. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, and Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:2855-2864.
44. Kuhmann SE, Platt EJ, Kozak SL, and Kabat D: Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 2000;74:7005-7015.
45. Reeves JD, Gallo SA, Ahmad N, et al.: Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002;99:16249-16254.
46. Blanpain C, Lee B, Tackoen M, et al.: Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood 2000;96:1638-1645.
47. Dabis F and Ekpini ER: HIV-1/AIDS and maternal and child health in Africa. Lancet 2002;359:2097-2104.
48. Tremblay CL, Kollmann C, Giguel F, Chou T-C, and Hirsch MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000;25:99-102.
49. Nagashima KA, Thompson DAD, Rosenfeld SI, Maddon PJ, Dragic T, and Olson WC: Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001;183:1121-1125.
50. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, and Hirsch MS: Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002;46:1336-1339.